Valeant completes Salix Pharmaceuticals acquisition

Valeant Pharmaceuticals International has completed the acquisition of Salix Pharmaceuticals.

Advertisement

Salix Pharmaceuticals focuses on the gastroenterology market. The company offers treatments such as XIFAXAN, RUCONEST, APRISO, UCERIS and RELISTOR.

More articles on gastroenterology:
5 most-read GI articles – March 23 to March 27
4 recent GI market updates to know
18 statistics on gastroenterologist habits & burnout

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.